Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Glaukos (GKOS)

Glaukos Q3 sales rise 24% to record $96.7 million; 2024 sales guidance raised

Positive Impact 4 of 5 earnings Written later

Glaukos reported third-quarter 2024 net sales of $96.7 million, up 24% from a year earlier, and narrowed its net loss to $21.4 million from $30.4 million. The company raised its full-year 2024 net sales guidance to $377 million to $379 million from $370 million to $376 million, which is a positive signal for shareholders on revenue trend, though the company still reported a GAAP net loss.

Key points

  • Q3 2024 net sales of $96.7 million, up 24% year over year; glaucoma sales $76.0 million, up 30%
  • Q3 2024 net loss of $21.4 million, or $0.39 per diluted share, versus $30.4 million, or $0.63, in Q3 2023
  • 2024 net sales guidance raised to $377 million to $379 million from $370 million to $376 million
  • Cash, short-term investments and restricted cash of $267.2 million as of September 30, 2024

The filing

CompanyGlaukos (GKOS)
Form8-K, current report
Filed with the SECNov 4, 2024, 4:10 PM ET
Accession number0001558370-24-014262

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.